The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete.
The reader should not assume that the information is accurate and complete.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 13F

FORM 13F INFORMATION TABLE

OMB APPROVAL
OMB Number:3235-0006
Expires:Oct 31, 2018
Estimated average burden
hours per response:23.8

COLUMN 1COLUMN 2COLUMN 3COLUMN 4COLUMN 5COLUMN 6COLUMN 7COLUMN 8
VALUESHRS ORSH/PUT/INVESTMENTOTHERVOTING AUTHORITY
NAME OF ISSUERTITLE OF CLASSCUSIP(x$1000)PRN AMTPRNCALLDISCRETIONMANAGERSOLESHAREDNONE
ABBVIE INC.COM00287Y109921,000SH SOLE 1,00000
ALLERGAN PLCSHSG0177J10873,045546,500SH SOLE 546,50000
BIOGEN INC.COM09062X103138,982461,858SH SOLE 461,85800
INNOVIVA INC.COM45781M10188,1415,051,100SH SOLE 5,051,10000
INTERCEPT PHARMACEUTICALS INC.COM45845P1085,44254,000SH SOLE 54,00000
IRONWOOD PHARMACEUTICALS INC.COM CL A46333X10864,7736,252,300SH SOLE 6,252,30000
MEDICINES CO.COM58468810553,2282,781,000SH SOLE 2,781,00000
MIRATI THERAPEUTICS INC.COM60468T105421,000SH SOLE 1,00000
PUMA BIOTECHNOLOGY INC.COM74587V10727,3301,343,000SH SOLE 1,343,00000
SHIRE PLCSPONSORED ADR82481R1061741,000SH SOLE 1,00000